ReviewJournal of thrombosis and thrombolysis2007
Streptokinase--the drug of choice for thrombolytic therapy.
Review in Journal of thrombosis and thrombolysis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 107 citations in OpenAlex.
- Intrapleural Fibrinolytic Therapy in the Management of Pediatric Pleural Empyema: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Mapping the Mutational Landscape for Streptokinase Binding to Plasminogen.bioRxiv : the preprint server for biology · 2026Article
- Emerging Elastic Micro-Nano Materials for Diagnosis and Treatment of Thrombosis.Research (Washington, D.C.) · 2025Review
- Okra polysaccharide mitigates carrageenan-induced thrombosis in mice by regulating inflammation and oxidative stress.Frontiers in pharmacology · 2025Article
- Assessment of clot-lysing and membrane-stabilizing capacity of ascorbic acid:Toxicology reports · 2024Article
- Maggot Kinase and Natural Thrombolytic Proteins.ACS omega · 2024Review
- Targeted drug delivery to the thrombus by fusing streptokinase with a fibrin-binding peptide (CREKA): anTherapeutic delivery · 2024Article
- Antarctic Krill Oil fromInternational journal of molecular sciences · 2023Article
- Thrombolytic Agents: Nanocarriers in Targeted Release.Molecules (Basel, Switzerland) · 2021Review
- Purification and Characterization of a Thrombolytic Enzyme Produced by a New Strain ofJournal of microbiology and biotechnology · 2021Article
- Leonurine Ameliorates Oxidative Stress and Insufficient Angiogenesis by Regulating the PI3K/Akt-eNOS Signaling Pathway in HOxidative medicine and cellular longevity · 2021Article
- Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.Molecular pharmaceutics · 2017Article
- The evolution of recombinant thrombolytics: Current status and future directions.Bioengineered · 2017Article
- An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.Pharmaceutical research · 2016Article
- Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.Toxicology and applied pharmacology · 2016Review
- Streptococcus agalactiae mural infective endocarditis in a structurally normal heart.Journal of community hospital internal medicine perspectives · 2016Article
- Pentoxifylline Increases Antiadhesion Effect of Streptokinase on Postoperative Adhesion Formation: Involvement of Fibrinolytic Pathway.The Indian journal of surgery · 2015Article
- Nanomedicine as a strategy to fight thrombotic diseases.Future science OA · 2015Review
- Shaping bio-inspired nanotechnologies to target thrombosis for dual optical-magnetic resonance imaging.Journal of materials chemistry. B · 2015Article
- Effects of organic extracts and their different fractions of five Bangladeshi plants on in vitro thrombolysis.BMC complementary and alternative medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis, the blockage of blood vessels with clots, can lead to acute myocardial infarction and ischemic stroke, both leading causes of death. Other than surgical interventions to remove or by pass the blockage, or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration of thrombolytic agents to dissolve the blood clot. This article describes a comprehensive review of streptokinase (SK). We discuss the biochemistry and molecular biology of SK, describing the mechanism of action, structures, confirmational properties, immunogenecity, chemical modification, and cloning and expression. The production and physico-chemical properties of this SK are also discussed. In this review, considering the properties and characteristics of SK that make it the drug of choice for thrombolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.